← The Wire
ANTXNasdaq
AN2 Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1880438
AN2 Therapeutics discovers and develops novel small-molecule therapeutics using boron chemistry for various diseases
$171M
Market cap
$5.03
Last close
-3.3%
1D
-6.8%
5D
324K
Volume
Price · last 39 sessions+3.7%
May 4L $3.82 · H $5.40Jun 29
81
Total filings
Jun 9, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 9, 20268-KReg FD Disclosure · Company UpdateJun 4, 202610-Q10-QMay 11, 20268-KResults of OperationsMay 11, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 2026424B5424B5Apr 20, 20268-KCompany UpdateApr 9, 20268-KExecutive ChangeMar 20, 202610-K10-KMar 17, 20268-KResults of OperationsMar 17, 20268-KMaterial Agreement · Equity IssuanceMar 10, 20268-KExecutive ChangeJan 29, 202610-Q10-QNov 12, 20258-KResults of OperationsNov 12, 202510-Q10-QAug 12, 20258-KCompany UpdateAug 12, 20258-KEquity IssuanceJun 20, 20258-KReg FD DisclosureJun 11, 20258-KShareholder VoteMay 27, 202510-Q10-QMay 13, 20258-KCompany UpdateMay 13, 20258-KReg FD DisclosureMay 1, 2025DEFA14ADEFA14AApr 10, 2025DEF 14ADEF 14AApr 10, 202510-K10-KMar 25, 20258-KResults of OperationsMar 25, 202510-Q10-QNov 13, 20248-KResults of OperationsNov 13, 20248-KExecutive ChangeNov 5, 20248-KMaterial Agreement · Security-Holder RightsAug 19, 202410-Q10-QAug 13, 20248-KResults of OperationsAug 13, 2024SC 13GSC 13GAug 12, 20248-KExecutive Change · Exit / Disposal CostsAug 8, 2024SC 13GSC 13GJul 3, 20248-KShareholder VoteJun 24, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 202410-K/A10-K/AMay 14, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 2024SC 13GSC 13GApr 10, 202410-K10-KMar 29, 20248-KResults of OperationsMar 28, 2024SC 13GSC 13GFeb 13, 20248-KCompany UpdateFeb 12, 202410-Q10-QNov 9, 20238-KResults of OperationsNov 9, 20238-KCompany UpdateSep 13, 20238-KExecutive ChangeSep 8, 2023424B5424B5Aug 16, 20238-KMaterial Agreement · Company UpdateAug 16, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 2023SC 13GSC 13GJul 25, 20238-KShareholder VoteJun 9, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 2023424B5424B5Apr 14, 202310-K10-KMar 29, 20238-KResults of OperationsMar 29, 2023SC 13GSC 13GFeb 13, 2023SC 13GSC 13GFeb 10, 202310-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KReg FD DisclosureOct 6, 202210-Q10-QAug 11, 20228-KResults of OperationsAug 11, 20228-KCompany UpdateJun 29, 202210-Q10-QMay 10, 20228-KResults of OperationsMay 10, 20228-KExecutive ChangeMay 9, 2022SC 13GAN2 THERAPEUTICS, INC.Apr 8, 2022SC 13GAN2 THERAPEUTICS, INC.Apr 8, 2022SC 13GTHE SCHEDULE 13GApr 4, 2022424B4424B4Mar 28, 2022S-1/AS-1/AMar 21, 2022
Insider Activity
In the 90 days to Mar 3, 2026: 5 sold $50K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 3, 2026 | Williams Sarah JoannePrincipal Accounting Officer | Sell | 327 | $1.06 | $347 |
| Jan 6, 2026 | Eizen Joshua MSee Remarks | Sell | 6,931 | $1.01 | $7K |
| Jan 6, 2026 | Chanda SanjayChief Development Officer | Sell | 5,956 | $1.01 | $6K |
| Jan 6, 2026 | Day LucyChief Financial Officer | Sell | 5,512 | $1.01 | $6K |
| Jan 6, 2026 | Prior Stephen DavidChief Strategy Officer | Sell | 2,858 | $1.01 | $3K |
| Jan 5, 2026 | Eizen Joshua MSee Remarks | Sell | 17,923 | $1.00 | $18K |
| Jan 5, 2026 | Prior Stephen DavidChief Strategy Officer | Sell | 3,604 | $1.00 | $4K |
| Jan 5, 2026 | Chanda SanjayChief Development Officer | Sell | 3,295 | $1.00 | $3K |
| Jan 5, 2026 | Day LucyChief Financial Officer | Sell | 3,295 | $1.00 | $3K |
| Nov 4, 2025 | Eizen Joshua MSee Remarks | Sell | 2,819 | $1.14 | $3K |
| Nov 4, 2025 | Prior Stephen DavidChief Strategy Officer | Sell | 765 | $1.14 | $872 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance